BioSpace News Archive

Business

Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.

May 6, 2020
·
8 min read
Business

OraSure Announces 2020 First Quarter Financial Results and Provides COVID-19 Update

OraSure Technologies, Inc. announced its financial results for the three months ended March 31, 2020 and provided an update on COVID-19 activities.

May 6, 2020
·
16 min read
Business

Axogen, Inc. Reports First Quarter 2020 Financial Results

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the first quarter ended March 31, 2020.

May 6, 2020
·
16 min read
Business

Neurocrine Biosciences Reports First Quarter 2020 Financial Results

INGREZZA® (valbenazine) First Quarter Net Product Sales of $231 Million with Approximately 41,500 TRx

May 6, 2020
·
18 min read
Business

Theravance Biopharma, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update

TD-0903, an investigational lung-selective nebulized Janus kinase inhibitor (JAKi) with the potential to treat Acute Lung Injury in hospitalized patients with COVID-19, has progressed to Phase 1 clinical testing

May 6, 2020
·
18 min read
Jazz Pharmaceuticals Announces Participation at Upcoming Virtual Investor Conferences

Jazz Pharmaceuticals plc announced that the company will webcast its corporate presentations at the following virtual investor conferences

May 6, 2020
·
2 min read
Business

Ligand Reports First Quarter 2020 Financial Results

Ligand Pharmaceuticals Incorporated reported financial results for the three months ended March 31, 2020 and provided an operating forecast and program updates.

May 6, 2020
·
23 min read
Drug Development

Enanta Announces Results of INTREPID Study of EDP-305 for the Treatment of Primary Biliary Cholangitis

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced topline results from its INTREPID Phase 2 study of EDP-305, a Farnesoid X receptor, in subjects with primary biliary cholangitis.

May 6, 2020
·
8 min read
BioCapital

Senseonics Announces Positive Coverage Decision for Eversense CGM from Several Blue Cross Blue Shield Plans

Blue Cross and Blue Shield coverage decisions add nearly 10 million covered lives for Eversense CGM

May 6, 2020
·
5 min read
BioMidwest

Home Use of GENOSYL® DS to Administer GENOSYL® gas for Inhalation for the Treatment of Pulmonary Hypertension Complicated by COVID-19 Infection Published in American Journal of Respiratory and Critical Care Medicine

Clinicians report on first at-home treatment of COVID-19 patient with VERO Biotech’s GENOSYL DS, an innovative, tankless delivery system for inhaled nitric oxide

May 6, 2020
·
6 min read